A 52-week Multi-center, Randomized, Double-blind, Placebo Controlled, Basket Study With an Open-label Extension to Investigate the Efficacy, Safety, and Tolerability of Remibrutinib (LOU064) in Chronic Inducible Urticaria (CINDU) in Adults Inadequately Controlled by H1-antihistamines
Latest Information Update: 07 Jun 2025
At a glance
- Drugs Remibrutinib (Primary)
- Indications Chronic urticaria; Cold Urticaria; Familial dermographism
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 31 Jan 2025 Planned primary completion date changed from 3 Jul 2026 to 30 Mar 2026.
- 05 Dec 2023 Planned primary completion date changed from 8 Jul 2026 to 3 Jul 2026.
- 05 Dec 2023 Status changed from not yet recruiting to recruiting.